Illumina Soars After Crushing Expectations for Q2
In response an upbeat second-quarter report and bullish guidance, shares of Illumina (NASDAQ: ILMN), a leading provider of genetic testing equipment, rose Wednesday morning. The stock was up by 13.3% as of 12:11 p.m. EDT.
Here's are the highlights from Illumina's second quarter:
Management credited the strong Q2 performance to huge demand for the company's new NovaSeq platform. Those results also allowed management to raise its guidance for rest of 2017:
Source: Fool.com
Illumina Inc. Stock
€128.88
5.140%
The stock is one of the favorites of our community with 31 Buy predictions and 3 Sell predictions.
As a result the target price of 160 € shows a positive potential of 24.15% compared to the current price of 128.88 € for Illumina Inc..
